Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 3 2Phase 2 2Phase 1 2

Status

Completed 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 11Neoplasm Metastasis 4Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Noonan Syndrome 1Non-Small Cell Lung Cancer With EGFR Mutation 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Mesothelioma 1Lung Diseases 1Inhibition, Psychological 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1

Interventions

pembrolizumab 43Nivolumab 24Gemcitabine 23Cyclophosphamide 22Paclitaxel 17Capecitabine 16fludarabine 15Ipilimumab 14aldesleukin 11Docetaxel 11130-nm albumin-bound paclitaxel 11Trastuzumab 10Cetuximab 10Bevacizumab 10Albumin-Bound Paclitaxel 9fludarabine phosphate 8Specimen Handling 8Interleukin-2 8Fluorouracil 8Cisplatin 8Biopsy 8Radiosurgery 7Oxaliplatin 7Irinotecan 7durvalumab 6avelumab 6Temozolomide 6Pemetrexed 6Leucovorin 6Carboplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm Metastasis × osimertinib × Clear all
NCT01802632 2026-04-20

AURA

AstraZeneca

Phase 1/2 Completed
603 enrolled 17 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT02917993 2026-02-09

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Incyte Corporation

Phase 1/2 Completed
59 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Inhibition, Psychological, Lung Neoplasms, Neoplasm Metastasis

NCT04770688 2024-08-15

AUTOMAN

Shanghai Chest Hospital

Phase 1/2 Completed
25 enrolled
Thoracic

Adenocarcinoma of Lung, Neoplasm Metastasis

NCT02803203 2023-09-22

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
49 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡